Previous 10 |
home / stock / oryzf / oryzf news
MADRID, Spain and CAMBRIDGE, Ma., May 07, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for th...
Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient mice models MADRID, Spain and CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company ...
Oryzon Genomics (ORYZF) announces the enrollment of the first patient in the PORTICO Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder ((BPD)), at the Vall d’Hebrón Hospital in Barcelona, Spain.PORTICO is a multicenter, double-blind, randomized...
Global Phase IIb adaptive trial recruiting patients in Europe and the U.S. The first interventional clinical trial in a real-world Borderline Personality Disorder (BPD) patient population Independent assessment of reduction of agitation and aggression, as well as overa...
Vafidemstat displayed good safety and tolerability in healthy young and elderly volunteers Paper confirms vafidemstat engages LSD1 target in humans and exhibits CNS penetration Vafidemstat is currently in Phase IIb in Borderline Personality Disorder MADRID,...
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received “Deci...
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...